Singapore's Medical Startup Raises Fresh Funding From East Ventures

AMILI, a Singapore-based precision gut microbiome company, has on Monday announced that it has secured new funding from venture capital firm East Ventures.

AMILI said in a statement that this fund strengthens its balance sheet, following the company’s series A funding in June 2022.

It said the fresh funds will be allocated towards expanding operations into Indonesia with the primary focus on addressing prevalent gut health issues using scientific approaches adapted to the Indonesian context.

“AMILI is honored and privileged to partner with East Ventures in enabling doctors and other health professionals to benefit their patients through microbiome science.”

“Beyond medicine, the microbiome is important in food and agritech, and AMILI also looks forward to contributing to innovations in this space, particularly in health-enhancing foods and addressing stunting and malnutrition,” said Jeremy Lim, Co-Founder and Chief Executive Officer of AMILI.

According to the statement, recent scientific developments and discoveries have led to the gut microbiome being increasingly recognized as the next frontier of human health.

The gut microbiome consists of trillions of bacteria, viruses, and fungi that live in the digestive tract.

It plays a key role in almost every aspect of human health, including digestion, immune function, mental health, and disease prevention.

There are many emerging applications of the gut microbiome, opening new possibilities for personalized medicine and transformative approaches to healthcare.

Founded in 2019 by Jeremy Lim, Co-Founder and Chief Executive Officer, and colleagues David Ong and Jonathan Lee, who led the region’s first gut microbiome transplants in the National University Hospital, Singapore in 2014, AMILI conducts advanced gut microbiome research and develops it into products and services.

AMILI also houses Southeast Asia’s only microbiome transplant bank and has supported transplants across the region.